Company intelligence / Profile preview

SENISCA

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

SENISCA is developing senotherapeutics that target the causes of age-related disease via RNA splicing regulation. Their technology has shown positive impacts on markers of disease modification in patient-derived models, and they are currently focused on IND data generation.

Therapeutic areas: PulmonologyRheumatologyOphthalmologyNeurology
Modalities: Oligonucleotidessmall moleculesRNA therapeutics
Industry: Biotech

Beyond the preview

Go deeper on SENISCA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENISCA.

Explore the full profile